Ph II Trial of a Novel Anti-angiogenic Agent in Combination With Chemotherapy for the Second-line Treatment of Metastatic Colorectal Cancer - Related Studies - ClinicalTrials.gov

Skip to Main Content

ClinicalTrials.gov

Beta test our new site.

(NLM Technical Bulletin)

Home Search Study Topics Glossary


	Full Text View


	Tabular View


	No Study Results Posted


	Related Studies

Ph II Trial of a Novel Anti-angiogenic Agent in Combination With Chemotherapy for the Second-line Treatment of Metastatic Colorectal Cancer

This study has been completed.

Study NCT00851045 Information provided by Bristol-Myers Squibb

First Received on February 23, 2009. Last Updated on January 13, 2012 History of Changes

Related Studies can be found by searching for the Conditions, Interventions, and Sponsors found in this study:

Conditions listed in this trial

Colorectal Cancer (CRC)

Additional conditions recognized in this trial

Colorectal Neoplasms

More general conditions related to this trial

Colonic Diseases
Digestive System Diseases
Digestive System Neoplasms
Gastrointestinal Diseases
Gastrointestinal Neoplasms
Intestinal Diseases
Intestinal Neoplasms
Neoplasms
Neoplasms by Site
Rectal Diseases

Interventions listed in this trial

Irinotecan
5-Fluorouracil (bolus)
5-Fluorouracil (infusional)
Leucovorin calcium
CT-322
Bevacizumab

Additional drug interventions recognized in this trial

Angiogenesis Inhibitors
Fluorouracil
Leucovorin
Levoleucovorin

Sponsors listed in this trial

Bristol-Myers Squibb

Back to top of Main Content